Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Himal Lal"'
Autor:
Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2691-2699 (2021)
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional co
Externí odkaz:
https://doaj.org/article/e0a61e1e225742c5b2e9ce10b62e0c70
Autor:
Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2865-2872 (2019)
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to
Externí odkaz:
https://doaj.org/article/2de77cc0739443df82239135c7c026b5
Autor:
Tino F. Schwarz, Stephanie Volpe, Gregory Catteau, Roman Chlibek, Marie Pierre David, Jan Hendrik Richardus, Himal Lal, Lidia Oostvogels, Karlis Pauksens, Stephanie Ravault, Lars Rombo, Gerard Sonder, Jan Smetana, Thomas Heineman, Adriana Bastidas
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 6, Pp 1370-1377 (2018)
Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least si
Externí odkaz:
https://doaj.org/article/1fea19af99134a6fa6c0023b1d606077
Autor:
Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, Himal Lal
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 5, Pp 1051-1058 (2017)
This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented histo
Externí odkaz:
https://doaj.org/article/246034a212a14e5dbbcaae429abe973c
Autor:
Peter Vink, Masanari Shiramoto, Masayuki Ogawa, Masahiro Eda, Martine Douha, Thomas Heineman, Himal Lal
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 3, Pp 574-578 (2017)
The impact of alternate routes of vaccine administration, subcutaneous (SC) or intramuscular (IM), on the safety and immunogenicity of herpes zoster subunit candidate vaccine (HZ/su) was assessed in Japanese adults aged ≥ 50 y. During this phase II
Externí odkaz:
https://doaj.org/article/237b134192944ce6ab2f2b075b5d3ac3
Autor:
Brandon, Essink, Charu, Sabharwal, Kevin, Cannon, Robert, Frenck, Himal, Lal, Xia, Xu, Vani, Sundaraiyer, Yahong, Peng, Lisa, Moyer, Michael W, Pride, Ingrid L, Scully, Kathrin U, Jansen, William C, Gruber, Daniel A, Scott, Wendy, Watson
Publikováno v:
Clinical Infectious Diseases. 75:390-398
Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated. Methods This pivota
Autor:
Himal Lal, Sarah Mirza, James Peterson, Brandon Essink, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Xia Xu, Kari Yacisin, Wendy Watson, Ingrid L. Scully
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional co
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
Autor:
Janet E. McElhaney, Desmond Curran, Charles P. Andrews, Laura Campora, Tiina Korhonen, Johan Berglund, Robert W. Johnson, Himal Lal, Zoe, Eugene Athan, Edward M. F. Leung, Shelly A. McNeil, Antonio Volpi, Thomas C. Heineman, Lidia Oostvogels, Sean Matthews, Javier Díez-Domingo, Myron J. Levin, Ferdinandus de Looze
Publikováno v:
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Background To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. Methods The assessment
Autor:
Won Suk Choi, Carline Vanden Abeele, Ilse Vastiau, Janet E. McElhaney, Himal Lal, Timo Vesikari, Myron J. Levin, Peter Van den Steen, Bruno Salaun, Tino F. Schwarz, Thomas C. Heineman, Meral Esen, Charles P. Andrews, Martina Kovac Choma, Lily Yin Weckx, Olivier Godeaux, Karlis Pauksens, Hideyuki Ikematsu, Zoe, Jan Smetana, Stéphanie Ravault, Shinn-Jang Hwang, Anthony L. Cunningham, Roman Chlibek
Publikováno v:
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
The Journal of Infectious Diseases
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
The Journal of Infectious Diseases
Background The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity re
Autor:
Lidia Oostvogels, Himal Lal, Naresh Aggarwal, Beate Moeckesch, Marta Lopez Fauqued, Thomas C. Heineman, Peter Van den Steen, Martine Douha, Tino F. Schwarz, Carine Claeys, Isabelle Schenkenberger, Olivier Godeaux, Katrijn Grupping
Publikováno v:
The Journal of Infectious Diseases
When the adjuvanted HZ subunit vaccine candidate was coadministered with a quadrivalent seasonal influenza vaccine, no interference in the immune responses were observed, and no safety concerns were identified.
Background The immunogenicity and
Background The immunogenicity and